epinephrine

ROUTE	ONSET	PEAK	DURATION
Inhaln	1 min	unknown	1–3 hr
SUBQ	5–10 min	20 min	<1–4 hr
IM	6–12 min	unknown	<1–4 hr
IV	rapid	20 min	20–30 min
Intranasal	5–10 min	20–30 min	1 hr

SC IM (Adults and Children ≥30 kg): Severe anaphylaxis: 0.3–0.5 mg (single dose not to exceed 0.5 mg); may repeat every 10–15 min as needed.
SC (Children <30 kg): Severe anaphylaxis: 0.01 mg/kg (not to exceed 0.3 mg/dose); may repeat every 10–15 min as needed; Auvi-Q or Symjepi (15–30 kg): 0.15 mg; may repeat if anaphylactic symptoms persist; Auvi-Q (7.5–15 kg): 0.1 mg; may repeat if anaphylactic symptoms persist.
IV (Adults ): Severe anaphylaxis: 0.1–0.25 mg every 5–15 min; may be followed by 1–4 mcg/min continuous infusion; Cardiopulmonary resuscitation (ACLS guidelines): 1 mg every 3–5 min; Bradycardia (ACLS guidelines): 2–10 mcg/min continuous infusion; Hypotension associated with septic shock: 0.05–2 mcg/kg/min continuous infusion; titrate every 10–15 min by 0.05–0.2 mcg/kg/min to achieve desired mean arterial pressure.
IV (Children ): Severe anaphylaxis: 0.1 mg (less in younger children); may be followed by 0.1 mcg/kg/min continuous infusion (may be ↑ up to 1.5 mcg/kg/min); Symptomatic bradycardia/pulseless arrest (PALS guidelines): 0.01 mg/kg; may be repeated every 3–5 min; higher doses (up to 0.1–0.2 mg/kg) may be considered; may also be given by the intraosseous route. May also be given by the endotracheal route in doses of 0.1–0.2 mg/kg diluted to a volume of 3–5 mL with normal saline followed by several positive pressure ventilations.
Inhaln (Adults ): Inhalation solution: 1 inhalation of 1% solution; may be repeated after 1–2 min; additional doses may be given every 3 hr; Racepinephrine: Via hand nebulizer, 2–3 inhalations of 2.25% solution; may repeat in 5 min with 2–3 more inhalations, up to 4–6 times daily.
Inhaln (Adults and Children ≥12 yr): Over-the-counter inhaler: 1–2 inhalations every 4 hr as needed (max = 8 inhalations/day).
Inhaln (Children >1 mo): 0.25–0.5 mL of 2.25% racemic epinephrine solution diluted in 3 mL normal saline.
(Adults and Children ≥30 kg): One spray (2 mg) administered into one nostril; if no clinical improvement in 5 min, may administer another spray (2 mg) in one nostril.
IV Intratracheal (Neonates ): 0.01–0.03 mg/kg every 3–5 min as needed.
Intracardiac (Adults ): 0.3–0.5 mg.
Endotracheal(Adults ): Cardiopulmonary resuscitation (ACLS guidelines): 2–2.5 mg.
(Adults and Children ≥6 yr): Nasal decongestant: Apply 1% solution as drops, spray, or with a swab.
Intraspinal(Adults and Children ): 0.2–0.4 mL of 1:1000 solution.
With Local Anesthetics(Adults and Children ): Use 1:200,000 solution with local anesthetic.

Availability

⬆ ⬇

(Generic available)

Inhalation aerosol: 0.125 mg/inhalation (160 metered inhalations)^OTC
Inhalation solution (racepinephrine): 2.25%
Nasal spray: 2 mg/0.1 mL
Premixed infusion: 2 mg/250 mL 0.9% NaCl; 4 mg/250 mL 0.9% NaCl; 5 mg/250 mL 0.9% NaCl; 8 mg/250 mL 0.9% NaCl; 10 mg/250 mL 0.9% NaCl
Solution for injection: 1 mg/mL (1:1000)
Solution for injection (autoinjectors) (Adrenaclick, Auvi-Q, EpiPen): 0.1 mg/0.1 mL (1:1000); 0.15 mg/0.15 mL (1:1000); 0.15 mg/0.3 mL (1:2000); 0.3 mg/0.3 mL (1:1000)
Solution for injection (prefilled syringes): 0.1 mg/mL (1:10,000); 0.15 mg/0.3 mL (1:2000); 0.3 mg/0.3 mL (1:1000)

Assessment

⬆ ⬇

Monitor IV infusion site for extravasation (cold, hard, pallid appearance). If blanching occurs, may change infusion site to allow effects of local vasoconstriction to subside. If extravasation occurs, infiltrate area liberally with 10–15 mL of 0.9% NaCl with 5–10 mg of phentolamine using a syringe with a fine needle within 12 hr of extravasation. Local hyperemic changes are immediate.
Bronchodilator: Assess lung sounds, respiratory pattern, HR, and BP before administration and during peak of medication. Note amount, color, and character of sputum produced.
Monitor pulmonary function tests before and periodically during therapy.
Observe for paradoxical bronchospasm (wheezing). If condition occurs, hold epinephrine and provide appropriate intervention.
- Observe patient for drug tolerance and rebound bronchospasm. Patients requiring >3 inhalation treatments in 24 hr should be under close supervision. If minimal or no relief is seen after 3–5 inhalation treatments within 6–12 hr, further treatment with aerosol alone is not recommended.
- Assess for hypersensitivity reaction (rash; urticaria; swelling of the face, lips, or eyelids). If condition occurs, hold epinephrine.
Vasopressor: Monitor BP, HR, ECG, and respiratory rate frequently during IV administration. Continuous ECG, hemodynamic parameters, and urine output should be monitored continuously during IV administration.If chest pain, arrhythmias, HR >110 bpm, or hypertension occur, consider dose adjustment or discontinue epinephrine depending on severity of symptoms.
Shock: Assess volume status. Correct hypovolemia prior to administering epinephrine IV.
Nasal Decongestant: Assess for nasal and sinus congestion prior to and periodically during therapy.

Lab Test Considerations:

May cause transient ↓ in serum potassium concentrations with nebulization or at higher than recommended doses.
- May ↑ blood glucose and serum lactic acid concentrations.

Toxicity and Overdose:

Symptoms of overdose include persistent agitation, chest pain or discomfort, ↓ BP, dizziness, hyperglycemia, hypokalemia, seizures, tachyarrhythmias, persistent trembling, and vomiting.
- Treatment includes discontinuing adrenergic bronchodilator and other beta-adrenergic agonists and symptomatic, supportive therapy. Cardioselective beta blockers are used cautiously because they may induce bronchospasm.

Implementation

⬆ ⬇

Do not confuse epinephrine with ephedrine.
High Alert: Patient harm or fatalities have occurred from medication errors with epinephrine. Epinephrine is available in various concentrations, strengths, and percentages and used for different purposes. Packaging labels may be confused or products incorrectly diluted. Dilutions should be prepared by a pharmacist. IV doses should be expressed in milligrams, not ampules, concentration, or volume. Prior to administration, have second practitioner independently check original order, dose calculations, concentration, route of administration, and infusion pump settings.
Medication should be administered promptly at the onset of bronchospasm.
- Use a tuberculin syringe with a 26-gauge ½-in. needle for SUBQ injection to ensure that correct amount of medication is administered.
- Tolerance may develop with prolonged or excessive use. Effectiveness may be restored by discontinuing for a few days and then readministering.
- Do not use solutions that are pinkish or brownish or that contain precipitates.
- For anaphylactic shock, volume replacement should be administered concurrently with epinephrine. Antihistamines and corticosteroids may be used in conjunction with epinephrine.
Administer one spray into either nostril. If no clinical improvement or symptoms worsen, administer 2nd dose to same nostril 5 min after first dose.
Inhaln: When using epinephrine inhalation solution, 10 drops of 1% base solution should be placed in the reservoir of the nebulizer.
- The 2.25% inhalation solution of racepinephrine must be diluted for use in the combination nebulizer/respirator.
- Allow 1–2 min to elapse between inhalations of epinephrine inhalation solution to make certain the 2nd inhalation is necessary.
- When epinephrine is used concurrently with corticosteroid or ipratropium inhalations, administer bronchodilator first and other medications 5 min apart to prevent toxicity from inhaled fluorocarbon propellants.
IM: SC: Administer into anterolateral thigh, through clothing if necessary, for anaphylaxis. Hold leg firmly to limit movement during injection to prevent lacerations, bent needles, and broken/embedded needles. Avoid injecting into gluteal muscle; may not be effective for anaphylaxis and may cause infection. Rotate injection sites to prevent tissue irritation or necrosis. Massage injection sites well after administration to enhance absorption and ↓ local vasoconstriction.
Endotracheal: Epinephrine can be injected directly into the bronchial tree via the endotracheal tube if the patient has been intubated. Perform 5 rapid insufflations; forcefully administer 10 mL containing 2–2.5 mg epinephrine (1 mg/mL) directly into tube; follow with 5 quick insufflations.

IV Administration:

IV Push: Diluent: 1:10,000 solution can be administered undiluted. Dilute 1 mg (1 mL) of a 1:1000 solution in 9 mL of 0.9% NaCl to prepare a 1:10,000 solution.Concentration: 0.1 mg/mL (1:10,000).
Rate: Administer each 1 mg (10 mL) of a 1:10,000 solution over ≥1 min; more rapid administration may be used during cardiac resuscitation. Follow each dose with 20 mL IV saline flush.
Continuous Infusion: Diluent: Dilute 1 mg (1 mL) of a 1:1000 solution in 250 mL of D5W or 0.9% NaCl. Protect from light. Infusion stable for 24 hr.Concentration: 4 mcg/mL.
Rate: See Route/Dosage section. Titrate to response (BP, HR, respiratory rate).
Y-Site Compatibility:
- alprostadil
- amikacin
- aminocaproic acid
- amiodarone
- amphotericin B lipid complex
- amphotericin B liposomal
- anidulafungin
- argatroban
- arsenic trioxide
- ascorbic acid
- asparaginase
- atracurium
- atropine
- azithromycin
- aztreonam
- benztropine
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- butorphanol
- caffeine citrate
- calcium chloride
- calcium gluconate
- cangrelor
- carboplatin
- caspofungin
- cefazolin
- cefoperazone
- cefotaxime
- cefotetan
- cefoxitin
- ceftazidime
- ceftolozane/tazobactam
- ceftriaxone
- cefuroxime
- chloramphenicol
- chlorothiazide
- chlorpromazine
- cisatracurium
- cisplatin
- clindamycin
- cyanocobalamin
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daptomycin
- daunorubicin
- dexmedetomidine
- dexamethasone
- dexrazoxane
- digoxin
- diltiazem
- diphenhydramine
- dobutamine
- docetaxel
- dopamine
- doxorubicin hydrochloride
- doxorubicin liposomal
- doxycycline
- edetate calcium disodium
- enalaprilat
- ephedrine
- epirubicin
- epoetin
- eptifibatide
- eravacycline
- ertapenem
- erythromycin
- esmolol
- etoposide
- etoposide phosphate
- famotidine
- fentanyl
- fluconazole
- fludarabine
- folic acid
- foscarnet
- fosphenytoin
- furosemide
- gemcitabine
- gentamicin
- glycopyrrolate
- granisetron
- heparin
- hydrocortisone sodium succinate
- hydromorphone
- hydroxyzine
- ibuprofen lysine
- idarubicin
- ifosfamide
- imipenem/cilastatin
- imipenem/cilastatin/relebactam
- insulin aspart,
- irinotecan
- isavuconazonium
- isoproterenol
- ketamine
- ketorolac
- labetalol
- leucovorin calcium
- levofloxacin
- lidocaine
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- meperidine
- meropenem/vaborbactam
- mesna
- methadone
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- midazolam
- milrinone
- mitomycin
- mitoxantrone
- morphine
- moxifloxacin
- multivitamin
- mycophenolate
- nafcillin
- nalbuphine
- naloxone
- nicardipine
- nitroglycerin
- nitroprusside
- norepinephrine
- octreotide
- ondansetron
- oritavancin
- oxacillin
- oxaliplatin
- oxytocin
- paclitaxel
- palonosetron
- pamidronate
- papaverine
- pemetrexed
- penicillin G potassium
- penicillin G sodium
- pentamidine
- phentolamine
- phenylephrine
- phytonadione
- piperacillin/tazobactam
- plazomicin
- potassium acetate
- potassium chloride
- procainamide
- prochlorperazine
- promethazine
- propranolol
- protamine
- pyridoxine
- remifentanil
- rocuronium
- sildenafil
- succinylcholine
- sulbactam/durlobactam
- tacrolimus
- tedizolid
- theophylline
- thiamine
- thiotepa
- tigecycline
- tirofiban
- tobramycin
- topotecan
- vancomycin
- vasopressin
- vecuronium
- verapamil
- vinblastine
- vincristine
- vinorelbine
- voriconazole
- zoledronic acid
Y-Site Incompatibility:
- acyclovir
- alemtuzumab
- amphotericin B deoxycholate
- azathioprine
- carmustine
- dacarbazine
- dantrolene
- diazepam
- diazoxide
- fluorouracil
- ganciclovir
- gemtuzumab ozogamicin
- indomethacin
- micafungin
- pentobarbital
- phenobarbital
- phenytoin
- sodium bicarbonate
- sulfamethoxazole/trimethoprim
- thiopental

Patient/Family Teaching

⬆ ⬇

Instruct patient to take medication exactly as directed. If on a scheduled dosing regimen, take a missed dose as soon as possible; space remaining doses at regular intervals. Do not double doses. Caution patient not to exceed recommended dose; may cause adverse effects, paradoxical bronchospasm, or loss of effectiveness.
- Instruct patient to seek emergency care immediately if shortness of breath is not relieved, worsens, or is accompanied by diaphoresis, dizziness, palpitations, or chest pain.
- Advise patient to consult health care professional before taking any OTC medications or alcoholic beverages concurrently with this therapy. Caution patient also to avoid smoking and other respiratory irritants.
- Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Inhaln: Review correct administration technique (aerosolization, IPPB) with patient.
- Do not spray inhaler near eyes.
- Advise patient to use bronchodilator first if using other inhalation medications, and allow 5 min to elapse before administering other inhalant medications, unless otherwise directed.
- Advise patient to rinse mouth with water after each inhalation dose to minimize dry mouth.
- Advise patient to maintain adequate fluid intake (2000–3000 mL/day) to help liquefy tenacious secretions.
Autoinjector or intranasal: Advise patients using epinephrine for anaphylaxis to always carry device with them. Instruct in appropriate administration and disposal. For use of autoinjector, instruct patient to remove gray safety cap, placing black tip on thigh at right angle to leg. Press hard into thigh until autoinjector functions, hold in place for 10 sec, remove, and discard properly. Massage injected area for 10 sec. For use of intranasal preparation, instruct patient to administer single dose in either nostril. If 2nd dose is needed, use same nostril, 5 min after initial dose. Do not sniff during or after use. Pedi: Teach caregivers signs and symptoms of anaphylaxis, correct administration techniques, and to get the child to a hospital as soon as possible. Instruct caregivers to teach child how to manage their allergy, how to self-administer, and what to do in an emergency. For children too young to administer epinephrine and who will be separated from caregiver, tell caregivers to always discuss allergy and use of medication with responsible adult.

Evaluation/Desired Outcomes

⬆ ⬇

Prevention or relief of bronchospasm.
- Increase in ease of breathing.
- Prevention of bronchospasm or reduced frequency of acute asthma attacks in patients with chronic asthma.
- Prevention of exercise-induced asthma.
Reversal of signs and symptoms of anaphylaxis.
↑in cardiac rate and output, when used in cardiac resuscitation.
↑BP, when used as a vasopressor.
Localization of local anesthetic.
↓sinus and nasal congestion.

US Brand Names

⬆ ⬇

Adrenaclick, Adrenalin, ~~AsthmaNefrin,~~ Auvi-Q, EpiPen, Neffy, Primatene Mist, Symjepi, ~~Twin-Ject~~

Canadian Brand Names

⬆ ⬇

Allerject, Anapen, Anapen Junior, Emerade, S-2 (racepinephrine)

Code

⬆

NDC Code

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5985- Epinephrine
  - 0093-5985-27- 2 CONTAINER in 1 CARTON (0093-5985-27) > 1 SYRINGE in 1 CONTAINER (0093-5985-19) > .3 mL in 1 SYRINGE

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5986- Epinephrine
  - 0093-5986-27- 2 CONTAINER in 1 CARTON (0093-5986-27) > 1 SYRINGE in 1 CONTAINER (0093-5986-19) > .3 mL in 1 SYRINGE

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1694- epinephrine
  - 0115-1694-30- 1 CASE in 1 CARTON (0115-1694-30) > 1 SYRINGE, GLASS in 1 CASE > .3 mL in 1 SYRINGE, GLASS

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1694- epinephrine
  - 0115-1694-49- 2 CASE in 1 CARTON (0115-1694-49) > 1 SYRINGE, GLASS in 1 CASE > .3 mL in 1 SYRINGE, GLASS

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1695- epinephrine
  - 0115-1695-30- 1 CASE in 1 CARTON (0115-1695-30) > 1 SYRINGE, GLASS in 1 CASE > .15 mL in 1 SYRINGE, GLASS

0115- Amneal Pharmaceuticals of New York LLC
- 0115-1695- epinephrine
  - 0115-1695-49- 2 CASE in 1 CARTON (0115-1695-49) > 1 SYRINGE, GLASS in 1 CASE > .15 mL in 1 SYRINGE, GLASS

0220- Boiron
- 0220-0076- Adrenalinum
  - 0220-0076-41- 30 [hp_C] in 1 TUBE (0220-0076-41)

0220- Boiron
- 0220-0078- Adrenalinum
  - 0220-0078-41- 200 [kp_C] in 1 TUBE (0220-0078-41)

0409- Hospira, Inc.
- 0409-4921- Epinephrine
  - 0409-4921-34- 10 CARTON in 1 PACKAGE (0409-4921-34) > 1 SYRINGE in 1 CARTON > 10 mL in 1 SYRINGE (0409-4921-20)

0781- Sandoz Inc.
- 0781-3442- SYMJEPI
  - 0781-3442-10- 1 SYRINGE in 1 CARTON (0781-3442-10) > .3 mL in 1 SYRINGE

0781- Sandoz Inc.
- 0781-3442- SYMJEPI
  - 0781-3442-20- 2 SYRINGE in 1 CARTON (0781-3442-20) > .3 mL in 1 SYRINGE

0781- Sandoz Inc.
- 0781-3448- SYMJEPI
  - 0781-3448-10- 1 SYRINGE in 1 CARTON (0781-3448-10) > .15 mL in 1 SYRINGE

0781- Sandoz Inc.
- 0781-3448- SYMJEPI
  - 0781-3448-20- 2 SYRINGE in 1 CARTON (0781-3448-20) > .15 mL in 1 SYRINGE

10129- Gingi-Pak a Division of the Belport
- 10129-006- Orostat 8%
  - 10129-006-02- 15 mL in 1 BOTTLE, GLASS (10129-006-02)

38739- Adamis Pharmaceuticals Corporation
- 38739-200- SYMJEPI
  - 38739-200-06- 6 CARTON in 1 CARTON (38739-200-06) > 1 SYRINGE in 1 CARTON (38739-200-01) > .3 mL in 1 SYRINGE

38739- Adamis Pharmaceuticals Corporation
- 38739-200- SYMJEPI
  - 38739-200-12- 6 CARTON in 1 CARTON (38739-200-12) > 2 SYRINGE in 1 CARTON (38739-200-02) > .3 mL in 1 SYRINGE

42023- Par Pharmaceutical, Inc.
- 42023-159- Adrenalin
  - 42023-159-25- 25 VIAL in 1 CARTON (42023-159-25) > 1 mL in 1 VIAL (42023-159-01)

42023- Par Pharmaceutical, Inc.
- 42023-168- Adrenalin
  - 42023-168-01- 1 VIAL in 1 CARTON (42023-168-01) > 30 mL in 1 VIAL

49502- Mylan Specialty L.P.
- 49502-101- Epinephrine
  - 49502-101-02- 2 CONTAINER in 1 CARTON (49502-101-02) > 1 SYRINGE, GLASS in 1 CONTAINER (49502-101-01) > .3 mL in 1 SYRINGE, GLASS

49502- Mylan Specialty L.P.
- 49502-102- Epinephrine
  - 49502-102-02- 2 CONTAINER in 1 CARTON (49502-102-02) > 1 SYRINGE, GLASS in 1 CONTAINER (49502-102-01) > .3 mL in 1 SYRINGE, GLASS

49502- Mylan Specialty L.P.
- 49502-500- EPIPEN
  - 49502-500-02- 2 CONTAINER in 1 CARTON (49502-500-02) > 1 SYRINGE, GLASS in 1 CONTAINER (49502-500-01) > .3 mL in 1 SYRINGE, GLASS

49502- Mylan Specialty L.P.
- 49502-501- EPIPEN JR
  - 49502-501-02- 2 CONTAINER in 1 CARTON (49502-501-02) > 1 SYRINGE, GLASS in 1 CONTAINER (49502-501-01) > .3 mL in 1 SYRINGE, GLASS

50090- A-S Medication Solutions
- 50090-1360- epinephrine
  - 50090-1360-0- 2 SYRINGE, GLASS in 1 CARTON (50090-1360-0) > .3 mL in 1 SYRINGE, GLASS

50090- A-S Medication Solutions
- 50090-2058- Epinephrine
  - 50090-2058-0- 10 SYRINGE in 1 PACKAGE (50090-2058-0) > 10 mL in 1 SYRINGE

50090- A-S Medication Solutions
- 50090-3155- epinephrine
  - 50090-3155-0- 2 CASE in 1 CARTON (50090-3155-0) > 1 mL in 1 CASE

50090- A-S Medication Solutions
- 50090-4506- epinephrine
  - 50090-4506-0- 2 CASE in 1 CARTON (50090-4506-0) > 1 mL in 1 CASE

50090- A-S Medication Solutions
- 50090-4544- Epinephrine
  - 50090-4544-0- 2 CONTAINER in 1 CARTON (50090-4544-0) > 1 mL in 1 CONTAINER

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1221- EPINEPHRINE
  - 51662-1221-1- 1 SYRINGE, GLASS in 1 CARTON (51662-1221-1) > 10 mL in 1 SYRINGE, GLASS

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1222- EPINEPHRINE
  - 51662-1222-1- 1 SYRINGE, GLASS in 1 CASE (51662-1222-1) > .15 mL in 1 SYRINGE, GLASS

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1223- EPINEPHRINE
  - 51662-1223-1- 1 SYRINGE, GLASS in 1 CASE (51662-1223-1) > .3 mL in 1 SYRINGE, GLASS

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1224- EPINEPHRINE
  - 51662-1224-1- 1 SYRINGE, GLASS in 1 CONTAINER (51662-1224-1) > .3 mL in 1 SYRINGE, GLASS

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1225- EPINEPHRINE
  - 51662-1225-1- 1 SYRINGE, GLASS in 1 CONTAINER (51662-1225-1) > .3 mL in 1 SYRINGE, GLASS

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1320- EPINEPHRINE
  - 51662-1320-1- .3 mL in 1 DOSE PACK (51662-1320-1)

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1320- EPINEPHRINE
  - 51662-1320-2- 2 DOSE PACK in 1 CARTON (51662-1320-2) > .3 mL in 1 DOSE PACK

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1321- EPINEPHRINE
  - 51662-1321-1- .15 mL in 1 DOSE PACK (51662-1321-1)

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1321- EPINEPHRINE
  - 51662-1321-2- 2 DOSE PACK in 1 CARTON (51662-1321-2) > .15 mL in 1 DOSE PACK

51662- HF Acquisition Co LLC, DBA HealthFirst
- 51662-1476- EPINEPHRINE
  - 51662-1476-1- 2 DOSE PACK in 1 CARTON (51662-1476-1) > .1 mL in 1 DOSE PACK

52584- General Injectables and Vaccines, Inc
- 52584-004- Epinephrine
  - 52584-004-34- 1 SYRINGE in 1 BAG (52584-004-34) > 10 mL in 1 SYRINGE

52584- General Injectables and Vaccines, Inc.
- 52584-103- EPINEPHRINE
  - 52584-103-01- 1 AMPULE in 1 BAG (52584-103-01) > 1 mL in 1 AMPULE

54288- BPI Labs, LLC
- 54288-103- Epinephrine
  - 54288-103-10- 10 AMPULE in 1 BOX (54288-103-10) > 1 mL in 1 AMPULE

60842- kaleo, Inc
- 60842-021- Auvi-Q
  - 60842-021-01- 2 DOSE PACK in 1 CARTON (60842-021-01) > .1 mL in 1 DOSE PACK

60842- kaleo, Inc
- 60842-022- Auvi-Q
  - 60842-022-01- 2 DOSE PACK in 1 CARTON (60842-022-01) > .15 mL in 1 DOSE PACK

60842- kaleo, Inc
- 60842-023- Auvi-Q
  - 60842-023-01- 2 DOSE PACK in 1 CARTON (60842-023-01) > .3 mL in 1 DOSE PACK

62250- Belcher Pharmaceuticals, LLC
- 62250-103- EPINEPHRINE
  - 62250-103-10- 10 AMPULE in 1 BOX (62250-103-10) > 1 mL in 1 AMPULE

63739- McKesson Corporation
- 63739-456- Epinephrine
  - 63739-456-05- 5 POUCH in 1 BOX (63739-456-05) > 1 CARTON in 1 POUCH (63739-456-21) > 1 SYRINGE, GLASS in 1 CARTON > 10 mL in 1 SYRINGE, GLASS

68428- Washington Homeopathic Products
- 68428-180- Adrenalinum
  - 68428-180-03- 75 PELLET in 1 VIAL, GLASS (68428-180-03)

68428- Washington Homeopathic Products
- 68428-180- Adrenalinum
  - 68428-180-05- 150 PELLET in 1 VIAL, GLASS (68428-180-05)

68428- Washington Homeopathic Products
- 68428-180- Adrenalinum
  - 68428-180-06- 1200 PELLET in 1 BOTTLE, GLASS (68428-180-06)

68428- Washington Homeopathic Products
- 68428-180- Adrenalinum
  - 68428-180-11- 300 PELLET in 1 BOTTLE, GLASS (68428-180-11)

68428- Washington Homeopathic Products
- 68428-180- Adrenalinum
  - 68428-180-12- 600 PELLET in 1 BOTTLE, GLASS (68428-180-12)

70385- Sina Health Inc
- 70385-2008- Epinephrine
  - 70385-2008-2- 2 AMPULE in 1 BAG (70385-2008-2) > 1 mL in 1 AMPULE

70385- Sina Health Inc
- 70385-2009- epinephrine
  - 70385-2009-1- 1 CASE in 1 BAG (70385-2009-1) > 1 SYRINGE, GLASS in 1 CASE > .3 mL in 1 SYRINGE, GLASS

70385- Sina Health Inc
- 70385-2017- epinephrine
  - 70385-2017-1- 1 CASE in 1 BAG (70385-2017-1) > 1 SYRINGE, GLASS in 1 CASE > .15 mL in 1 SYRINGE, GLASS

70518- REMEDYREPACK INC.
- 70518-0528- Epinephrine
  - 70518-0528-0- 10 CARTON in 1 PACKAGE (70518-0528-0) > 1 SYRINGE in 1 CARTON > 10 mL in 1 SYRINGE

70518- REMEDYREPACK INC.
- 70518-1215- Epinephrine
  - 70518-1215-0- 10 AMPULE in 1 BOX (70518-1215-0) > 1 mL in 1 AMPULE

70518- REMEDYREPACK INC.
- 70518-1224- EPIPEN
  - 70518-1224-0- 2 CONTAINER in 1 CARTON (70518-1224-0) > 1 SYRINGE, GLASS in 1 CONTAINER > .3 mL in 1 SYRINGE, GLASS

70518- REMEDYREPACK INC.
- 70518-2048- epinephrine
  - 70518-2048-0- 2 CASE in 1 CARTON (70518-2048-0) > 1 SYRINGE, GLASS in 1 CASE > .3 mL in 1 SYRINGE, GLASS

70518- REMEDYREPACK INC.
- 70518-2283- Epinephrine
  - 70518-2283-0- 2 CONTAINER in 1 CARTON (70518-2283-0) > 1 SYRINGE in 1 CONTAINER > .3 mL in 1 SYRINGE

71872- Medical Purchasing Solutions, LLC
- 71872-7007- epinephrine
  - 71872-7007-1- 1 CASE in 1 BAG (71872-7007-1) > 1 SYRINGE, GLASS in 1 CASE > .15 mL in 1 SYRINGE, GLASS

71872- Medical Purchasing Solutions, LLC
- 71872-7040- Epinephrine
  - 71872-7040-1- 1 CARTON in 1 BAG (71872-7040-1) > 1 VIAL in 1 CARTON > 10 mL in 1 VIAL

71872- Medical Purchasing Solutions, LLC
- 71872-7103- epinephrine
  - 71872-7103-1- 1 CASE in 1 BAG (71872-7103-1) > 1 SYRINGE, GLASS in 1 CASE > .3 mL in 1 SYRINGE, GLASS

71872- Medical Purchasing Solutions, LLC
- 71872-7117- Epinephrine
  - 71872-7117-1- 1 AMPULE in 1 BAG (71872-7117-1) > 1 mL in 1 AMPULE

71872- Medical Purchasing Solutions, LLC
- 71872-7120- Epinephrine
  - 71872-7120-1- 1 CARTON in 1 BAG (71872-7120-1) > 1 SYRINGE in 1 CARTON > 10 mL in 1 SYRINGE

71872- Medical Purchasing Solutions, LLC
- 71872-7134- Epinephrine
  - 71872-7134-1- 1 CONTAINER in 1 BAG (71872-7134-1) > 1 SYRINGE, GLASS in 1 CONTAINER > .3 mL in 1 SYRINGE, GLASS

71872- Medical Purchasing Solutions, LLC
- 71872-7135- Epinephrine
  - 71872-7135-1- 1 CONTAINER in 1 BAG (71872-7135-1) > 1 SYRINGE, GLASS in 1 CONTAINER > .3 mL in 1 SYRINGE, GLASS

71872- Medical Purchasing Solutions, LLC
- 71872-7172- Auvi-Q
  - 71872-7172-1- 1 DOSE PACK in 1 BAG (71872-7172-1) > .15 mL in 1 DOSE PACK

71872- Medical Purchasing Solutions, LLC
- 71872-7173- Auvi-Q
  - 71872-7173-1- 1 DOSE PACK in 1 BAG (71872-7173-1) > .3 mL in 1 DOSE PACK

71919- Washington Homeopathic Products
- 71919-014- Adrenalinum
  - 71919-014-07- 15 mL in 1 VIAL, GLASS (71919-014-07)

71919- Washington Homeopathic Products
- 71919-014- Adrenalinum
  - 71919-014-08- 30 mL in 1 VIAL, GLASS (71919-014-08)

71919- Washington Homeopathic Products
- 71919-014- Adrenalinum
  - 71919-014-09- 50 mL in 1 BOTTLE, GLASS (71919-014-09)

71919- Washington Homeopathic Products
- 71919-014- Adrenalinum
  - 71919-014-10- 100 mL in 1 BOTTLE, GLASS (71919-014-10)

76329- International Medication Systems, Limited
- 76329-3316- Epinephrine
  - 76329-3316-1- 10 VIAL in 1 PACKAGE (76329-3316-1) > 10 mL in 1 VIAL

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆

Pronunciation

Classifications

Indications

Action

Pharmacokinetics

Time/Action Profile

Contraind./Precautions

Adv. Reactions/Side Effects

Interactions

Route/Dosage